newsfilter
← Earnings
Earnings Releases·

Century Therapeutics — Third Quarter 2026 Earnings Summary

Century Therapeutics reported a net loss of $23.5 million for the third quarter ended September 30, 2026, with research and development expenses decreasing to $18.1 million due to portfolio prioritization. The company maintains a cash position of $174.1 million, providing a runway into the first quarter of 2029. Nonclinical data for its CNTY-813 therapy demonstrated sustained normoglycemia in diabetic mice, supporting an anticipated IND submission in the fourth quarter of 2026. Additionally, the CD19-targeted CAR-iT cell therapy CNTY-308 remains on track to enter clinical trials in 2026 following alignment with health authorities.

Company
CENTURY THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology